Immix Biopharma, Inc. — Form 8-K
Filed September 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Immix Biopharma priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share on September 29, 2026, generating gross proceeds of approximately $125 million. J.P. Morgan Securities LLC acted as sole book-running manager. The company intends to use net proceeds for NXC-201 development, working capital, and general corporate purposes. Closing was expected September 30, 2026.
Why this rating
Substantial capital raise (~$125M gross) represents ~3.5x company's $35.7M market cap—material liquidity infusion for clinical-stage biotech. Positive for runway and development.
Tradability signal
NO TRADE
No trade: positive news with only -1.8% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.33% over 4 hrs, n=139). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $10.40 ▼ 0.05% | at our read · unknown $10.40 | +10 min · unknown $10.18 ▼ 2.16% | +30 min · unknown $10.09 ▼ 3.08% | +1 hr · unknown $9.92 ▼ 4.66% | +4 hrs · unknown $10.44 ▲ 0.34% |
The stock had already moved +0.05% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.